153 related articles for article (PubMed ID: 31026449)
21. Prostate cancer-associated SPOP mutations lead to genomic instability through disruption of the SPOP-HIPK2 axis.
Jin X; Qing S; Li Q; Zhuang H; Shen L; Li J; Qi H; Lin T; Lin Z; Wang J; Cao X; Yang J; Ma Q; Cong L; Xi Y; Fang S; Meng X; Gong Z; Ye M; Wang S; Wang C; Gao K
Nucleic Acids Res; 2021 Jul; 49(12):6788-6803. PubMed ID: 34133717
[TBL] [Abstract][Full Text] [Related]
22. SPOP Promotes Nanog Destruction to Suppress Stem Cell Traits and Prostate Cancer Progression.
Zhang J; Chen M; Zhu Y; Dai X; Dang F; Ren J; Ren S; Shulga YV; Beca F; Gan W; Wu F; Lin YM; Zhou X; DeCaprio JA; Beck AH; Lu KP; Huang J; Zhao C; Sun Y; Gao X; Pandolfi PP; Wei W
Dev Cell; 2019 Feb; 48(3):329-344.e5. PubMed ID: 30595538
[TBL] [Abstract][Full Text] [Related]
23. The Roles of SPOP in DNA Damage Response and DNA Replication.
Maekawa M; Higashiyama S
Int J Mol Sci; 2020 Oct; 21(19):. PubMed ID: 33023230
[TBL] [Abstract][Full Text] [Related]
24. SPOP-mutant prostate cancer: Translating fundamental biology into patient care.
Bernasocchi T; Theurillat JP
Cancer Lett; 2022 Mar; 529():11-18. PubMed ID: 34974131
[TBL] [Abstract][Full Text] [Related]
25. Higher-order SPOP assembly reveals a basis for cancer mutant dysregulation.
Cuneo MJ; O'Flynn BG; Lo YH; Sabri N; Mittag T
Mol Cell; 2023 Mar; 83(5):731-745.e4. PubMed ID: 36693379
[TBL] [Abstract][Full Text] [Related]
26. AMPK Promotes SPOP-Mediated NANOG Degradation to Regulate Prostate Cancer Cell Stemness.
Wang X; Jin J; Wan F; Zhao L; Chu H; Chen C; Liao G; Liu J; Yu Y; Teng H; Fang L; Jiang C; Pan W; Xie X; Li J; Lu X; Jiang X; Ge X; Ye D; Wang P
Dev Cell; 2019 Feb; 48(3):345-360.e7. PubMed ID: 30595535
[TBL] [Abstract][Full Text] [Related]
27. Snail promotes prostate cancer migration by facilitating SPOP ubiquitination and degradation.
Lv W; Huan M; Yang W; Gao Y; Wang K; Xu S; Zhang M; Ma J; Wang X; Chen Y; Li L
Biochem Biophys Res Commun; 2020 Aug; 529(3):799-804. PubMed ID: 32736710
[TBL] [Abstract][Full Text] [Related]
28. Mutational and expressional analyses of SPOP, a candidate tumor suppressor gene, in prostate, gastric and colorectal cancers.
Kim MS; Je EM; Oh JE; Yoo NJ; Lee SH
APMIS; 2013 Jul; 121(7):626-33. PubMed ID: 23216165
[TBL] [Abstract][Full Text] [Related]
29. Opposing Roles of
Cavalcante L; Deshmukh SK; Ribeiro JR; Carneiro BA; Dizon DS; Angara K; Mattox T; Wu S; Xiu J; Walker P; Oberley M; Nabhan C; Huang H; Antonarakis ES
JCO Precis Oncol; 2023 Sep; 7():e2300088. PubMed ID: 37677121
[TBL] [Abstract][Full Text] [Related]
30. SPOP mutation drives prostate neoplasia without stabilizing oncogenic transcription factor ERG.
Shoag J; Liu D; Blattner M; Sboner A; Park K; Deonarine L; Robinson BD; Mosquera JM; Chen Y; Rubin MA; Barbieri CE
J Clin Invest; 2018 Jan; 128(1):381-386. PubMed ID: 29202479
[TBL] [Abstract][Full Text] [Related]
31. Deregulation of SPOP in Cancer.
Zhang H; Jin X; Huang H
Cancer Res; 2023 Feb; 83(4):489-499. PubMed ID: 36512624
[TBL] [Abstract][Full Text] [Related]
32. SPOP promotes CDCA5 degradation to regulate prostate cancer progression via the AKT pathway.
Luo Z; Wang J; Zhu Y; Sun X; He C; Cai M; Ma J; Wang Y; Han S
Neoplasia; 2021 Oct; 23(10):1037-1047. PubMed ID: 34509929
[TBL] [Abstract][Full Text] [Related]
33. Dual functions of SPOP and ERG dictate androgen therapy responses in prostate cancer.
Bernasocchi T; El Tekle G; Bolis M; Mutti A; Vallerga A; Brandt LP; Spriano F; Svinkina T; Zoma M; Ceserani V; Rinaldi A; Janouskova H; Bossi D; Cavalli M; Mosole S; Geiger R; Dong Z; Yang CG; Albino D; Rinaldi A; Schraml P; Linder S; Carbone GM; Alimonti A; Bertoni F; Moch H; Carr SA; Zwart W; Kruithof-de Julio M; Rubin MA; Udeshi ND; Theurillat JP
Nat Commun; 2021 Feb; 12(1):734. PubMed ID: 33531470
[TBL] [Abstract][Full Text] [Related]
34. The ubiquitin ligase adaptor SPOP in cancer.
Cuneo MJ; Mittag T
FEBS J; 2019 Oct; 286(20):3946-3958. PubMed ID: 31495053
[TBL] [Abstract][Full Text] [Related]
35. Deficiency in SPOP-mediated ubiquitination and degradation of TIAM1 promotes gastric cancer progression.
Liu F; Zhang T; Sun X; Liu Z; Xu W; Dai X; Zhang X
Biochim Biophys Acta Mol Basis Dis; 2024 Mar; 1870(3):167032. PubMed ID: 38246227
[TBL] [Abstract][Full Text] [Related]
36. Speckle-type POZ protein suppresses lipid accumulation and prostate cancer growth by stabilizing fatty acid synthase.
Gang X; Xuan L; Zhao X; Lv Y; Li F; Wang Y; Wang G
Prostate; 2019 Jun; 79(8):864-871. PubMed ID: 30955223
[TBL] [Abstract][Full Text] [Related]
37. ERK1/2 inhibits Cullin 3/SPOP-mediated PrLZ ubiquitination and degradation to modulate prostate cancer progression.
Fan Y; Hou T; Dan W; Zhu Y; Liu B; Wei Y; Wang Z; Gao Y; Zeng J; Li L
Cell Death Differ; 2022 Aug; 29(8):1611-1624. PubMed ID: 35194188
[TBL] [Abstract][Full Text] [Related]
38. Androgen receptor is the key transcriptional mediator of the tumor suppressor SPOP in prostate cancer.
Geng C; Rajapakshe K; Shah SS; Shou J; Eedunuri VK; Foley C; Fiskus W; Rajendran M; Chew SA; Zimmermann M; Bond R; He B; Coarfa C; Mitsiades N
Cancer Res; 2014 Oct; 74(19):5631-43. PubMed ID: 25274033
[TBL] [Abstract][Full Text] [Related]
39. SPOP E3 Ubiquitin Ligase Adaptor Promotes Cellular Senescence by Degrading the SENP7 deSUMOylase.
Zhu H; Ren S; Bitler BG; Aird KM; Tu Z; Skordalakes E; Zhu Y; Yan J; Sun Y; Zhang R
Cell Rep; 2015 Nov; 13(6):1183-1193. PubMed ID: 26527005
[TBL] [Abstract][Full Text] [Related]
40. Tumor suppressor SPOP ubiquitinates and degrades EglN2 to compromise growth of prostate cancer cells.
Zhang L; Peng S; Dai X; Gan W; Nie X; Wei W; Hu G; Guo J
Cancer Lett; 2017 Apr; 390():11-20. PubMed ID: 28089830
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
